Skip to main content
OpenTrials
Completed

NCT Number: NCT01632059

Examination of ADMA Serum Level and DDAH II

Examination of ADMA (Asymmetric-Dimethylarginine)-serum level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in patients with severe Sepsis and septic shock as prognostic value.

This study looks into ADMA as a good prognostic factor for sepsis. Further more the dependency of the ADMA level to the DDAH II polymorphisms is reviewed this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Septic Shock Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Shock Shock, Septic Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätskrankenhaus Hamburg Eppendorf

Hamburg, 20246, Germany

About this study

Secondary targets are the mortality (28 days ICU), the length of hospitalisation in ICU and peripheral station, the severity of the illness (SAPS II score), the SOFA-score values in the progress and the procalcitonin values in the progress

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >18 y/o
  • sepsis
  • septical shock

Exclusion criteria

  • primary cardiogenic shock
  • pregnancy
  • breastfeeding
  • non compliance
  • moribund status

Treatment and study plan

Primary outcomes

  1. ADMA serum levels

    Time frame: 7 days

    measuring of ADMA serum levels on day 1, 3, 7

Secondary outcomes

  1. 28 day mortality

    Time frame: 28 day

  2. hospitalisation (ICU and peripheral)

    Time frame: 28 days

  3. severity of illness

    Time frame: 28 days

  4. DDAH Ii polymorphism

    Time frame: 28 days

Sponsors and collaborators

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf

Other

Registry information

Official study title

Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value

Acronym: ADSeS

Important dates

Study start
2012
Primary completion
2013
Study completion
2017
First posted
Jun 29, 2012
Registry last updated
Aug 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.